These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 25692619)

  • 1. Therapeutic approach guided by genetic alteration: use of MTOR inhibitor in renal medullary carcinoma with loss of PTEN expression.
    Lipkin JS; Rizvi SM; Gatalica Z; Sarwani NE; Holder SL; Kaag M; Drabick JJ; Joshi M
    Cancer Biol Ther; 2015; 16(1):28-33. PubMed ID: 25692619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma.
    Beckermann KE; Jolly PC; Kim JY; Bordeaux J; Puzanov I; Rathmell WK; Johnson DB
    J Immunother Cancer; 2017; 5():1. PubMed ID: 28105368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination Therapy With Bortezomib in Renal Medullary Carcinoma: A Case Series.
    Ryan A; Tawagi K; VanderVeen N; Matrana M; Vasquez R
    Clin Genitourin Cancer; 2021 Dec; 19(6):e395-e400. PubMed ID: 34565708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Model Linking Sickle Cell Hemoglobinopathies and SMARCB1 Loss in Renal Medullary Carcinoma.
    Msaouel P; Tannir NM; Walker CL
    Clin Cancer Res; 2018 May; 24(9):2044-2049. PubMed ID: 29440190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy.
    Schaeffer EM; Guzzo TJ; Furge KA; Netto G; Westphal M; Dykema K; Yang X; Zhou M; Teh BT; Pavlovich CP
    BJU Int; 2010 Jul; 106(1):62-5. PubMed ID: 20002663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma.
    Roldan-Romero JM; Beuselinck B; Santos M; Rodriguez-Moreno JF; Lanillos J; Calsina B; Gutierrez A; Tang K; Lainez N; Puente J; Castellano D; Esteban E; Climent MA; Arranz JA; Albersen M; Oudard S; Couchy G; Caleiras E; Montero-Conde C; Cascón A; Robledo M; Rodríguez-Antona C; García-Donas J;
    Int J Cancer; 2020 Mar; 146(5):1435-1444. PubMed ID: 31335987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma.
    Msaouel P; Hong AL; Mullen EA; Atkins MB; Walker CL; Lee CH; Carden MA; Genovese G; Linehan WM; Rao P; Merino MJ; Grodman H; Dome JS; Fernandez CV; Geller JI; Apolo AB; Daw NC; Hodges HC; Moxey-Mims M; Wei D; Bottaro DP; Staehler M; Karam JA; Rathmell WK; Tannir NM
    Clin Genitourin Cancer; 2019 Feb; 17(1):1-6. PubMed ID: 30287223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Future perspectives for mTOR inhibitors in renal cell cancer treatment.
    Czarnecka AM; Kornakiewicz A; Lian F; Szczylik C
    Future Oncol; 2015; 11(5):801-17. PubMed ID: 25757683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platinum plus bortezomib for the treatment of pediatric renal medullary carcinoma: Two cases.
    Carden MA; Smith S; Meany H; Yin H; Alazraki A; Rapkin LB
    Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28052556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel renal medullary carcinoma cell lines, UOK353 and UOK360, provide preclinical tools to identify new therapeutic treatments.
    Wei D; Yang Y; Ricketts CJ; Vocke CD; Ball MW; Sourbier C; Wangsa D; Wangsa D; Guha R; Zhang X; Wilson K; Chen L; Meltzer PS; Ried T; Thomas CJ; Merino MJ; Linehan WM
    Genes Chromosomes Cancer; 2020 Aug; 59(8):472-483. PubMed ID: 32259323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal Medullary Carcinoma: A Surveillance, Epidemiology, and End Results (SEER) Analysis.
    Haupt T; Akinyemi O; Raju RA; Wadley AE; Nnorom S; Aponte V; Thelus J; Tonkin JB; Coleman PW; Metwalli AR
    J Surg Res; 2023 Dec; 292():1-6. PubMed ID: 37567029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors.
    Philip CA; Laskov I; Beauchamp MC; Marques M; Amin O; Bitharas J; Kessous R; Kogan L; Baloch T; Gotlieb WH; Yasmeen A
    BMC Cancer; 2017 Sep; 17(1):638. PubMed ID: 28886696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective Response to Mammalian Target of Rapamycin Inhibition in a Patient with Metastatic Renal Cell Carcinoma Bearing TSC1 Mutation.
    Ali SM; Stephens PJ; Miller VA; Ross JS; Pal SK
    Eur Urol; 2015 Aug; 68(2):341-3. PubMed ID: 25796537
    [No Abstract]   [Full Text] [Related]  

  • 14. Renal medullary carcinoma in a young mixed-race man in Japan.
    Toriyama A; Izumi H; Tomita S; Nagashima Y; Ueda Y; Aoki Y; Tsujimura A; Yao T; Hino O
    Pathol Int; 2019 Apr; 69(4):241-245. PubMed ID: 30843648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.
    Ghosh AP; Marshall CB; Coric T; Shim EH; Kirkman R; Ballestas ME; Ikura M; Bjornsti MA; Sudarshan S
    Oncotarget; 2015 Jul; 6(20):17895-910. PubMed ID: 26255626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy.
    Pantuck AJ; Seligson DB; Klatte T; Yu H; Leppert JT; Moore L; O'Toole T; Gibbons J; Belldegrun AS; Figlin RA
    Cancer; 2007 Jun; 109(11):2257-67. PubMed ID: 17440983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal medullary carcinoma: case report and review of the literature.
    Noguera-Irizarry WG; Hibshoosh H; Papadopoulos KP
    Am J Clin Oncol; 2003 Oct; 26(5):489-92. PubMed ID: 14528077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal cell carcinoma, unclassified with medullary phenotype: poorly differentiated adenocarcinomas overlapping with renal medullary carcinoma.
    Sirohi D; Smith SC; Ohe C; Colombo P; Divatia M; Dragoescu E; Rao P; Hirsch MS; Chen YB; Mehra R; Amin MB
    Hum Pathol; 2017 Sep; 67():134-145. PubMed ID: 28716439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes.
    Carlo MI; Chaim J; Patil S; Kemel Y; Schram AM; Woo K; Coskey D; Nanjangud GJ; Voss MH; Feldman DR; Hsieh JJ; Hakimi AA; Chen YB; Motzer RJ; Lee CH
    Clin Genitourin Cancer; 2017 Dec; 15(6):e987-e994. PubMed ID: 28558987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent Advances in Renal Medullary Carcinoma.
    Su Y; Hong AL
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.